1. Updates and Perspectives in Diabetic Dyslipidemia

2. Program Goals

3. Lifetime Risk for CVD Based on Risk Factors

4. T2D Is Often Associated With a Diabetic Dyslipidemia Profile

5. Non-HDL-C Is a Better Measure of Risk Than LDL-C When TGs Are High

6. Non-HDL-C: An Important Target Under Statin Therapy

7. 2016 Canadian Cardiovascular Society Guidelines on Managing Dyslipidemia

8. 2016 ESC/EAS Guidelines for the Management of Dyslipidemias

9. AACE: CAD Risk Categories and LDL-C Treatment Goals

10. NLA Recommendations

11. Low Achievement of Lipid Goals Despite Statin Therapy

12. PCSK9 Inhibitors and LDL-C Lowering in T2D

13. ODYSSEY DM-INSULIN Rationale and Objectives

14. ODYSSEY DM-INSULIN T1D/T2D Study Design

15. Alirocumab Significantly Reduced LDL-C From Baseline to Week 24 vs Placebo (ITT)* T1D and T2D Population

16. Glycemic-Related Parameters Absolute Levels for T2D and T1D Populations

17. Overview of TEAEs and Antidrug Antibodies Overall Population

18. PCSK9 Inhibitor Injection Site Reactions

19. ODYSSEY DM-DYSLIPIDEMIA Study Design

20. Investigator Made UC Choice Before Randomization

21. Percent Change in Non-HDL-C From Baseline to Week 24 vs UC or Fenofibrate (Primary Efficacy Endpoint; ITT*)

22. Selected Secondary Lipid Parameters at Week 24 vs UC (ITT*)

23. FOURIER Trial Design

24. FOURIER: Diabetes at Baseline

25. FOURIER in Patients With Diabetes: Effect of Evolocumab on Primary Endpoint

26. FOURIER in Patients With Diabetes: Effect of Evolocumab on Key Secondary Endpoint

27. New-Onset Diabetes in FOURIER

28. ODYSSEY OUTCOMES: Study Design

29. Interprofessional Care Team Approach

30. Summary

31. Abbreviations

32. Abbreviations (cont)

33. Abbreviations (cont)

34. Abbreviations (cont)

35. Abbreviations (cont)